We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ultrasound Guided Adductor Canal Block Versus Femoral Nerve Block for Quadriceps Strength and Fall-risk

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01655277
Recruitment Status : Completed
First Posted : August 1, 2012
Last Update Posted : August 1, 2012
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Our objective was to determine if an ultrasound guided ACB can preserve quadriceps strength, thus minimizing weakness of knee extension compared with ultrasound guided femoral nerve block. Our primary outcome was the percent of maximum voluntary isometric contraction (MVIC) of knee extension preserved at 30 mins after either an ACB or FNB. Secondary outcomes included MVIC of knee extension at 60 min, hip adduction at 30 and 60 mins, and assessment of fall risk with the Berg Balance Scale (BBS) at 30 minutes.

Condition or disease Intervention/treatment Phase
Quadriceps Muscle Weakness Adductor Muscle Weakness Fall Risk Procedure: Ultrasound Guided Adductor Canal Block Procedure: Ultrasound Guided Femoral Nerve Block Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effects of Ultrasound Guided Adductor Canal Block Versus Femoral Nerve Block on Quadriceps Strength and Fall-risk: a Blinded Randomized Trial of Volunteers
Study Start Date : February 2012
Primary Completion Date : June 2012
Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Falls Ultrasound
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Adductor Canal block first
This arm received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
Procedure: Ultrasound Guided Adductor Canal Block Procedure: Ultrasound Guided Femoral Nerve Block
Experimental: Femoral nerve block first
This arm received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
Procedure: Ultrasound Guided Adductor Canal Block Procedure: Ultrasound Guided Femoral Nerve Block


Outcome Measures

Primary Outcome Measures :
  1. Percent of maximum voluntary isometric contraction (MVIC) of knee extension preserved at 30 mins after either an ACB or FNB [ Time Frame: At 30 minutes ]

Secondary Outcome Measures :
  1. Percent of maximum voluntary isometric contraction (MVIC) of knee extension preserved at 60 mins after either an ACB or FNB [ Time Frame: At 60 minutes ]
  2. Percent of maximum voluntary isometric contraction (MVIC) of hip adduction preserved at 30 mins after either an ACB or FNB [ Time Frame: At 30 minutes ]
  3. Percent of maximum voluntary isometric contraction (MVIC) of hip adduction preserved at 60 mins after either an ACB or FNB [ Time Frame: At 60 minutes ]
  4. Assessment of fall risk with the Berg Balance Scale (BBS) at 30 minutes after the first nerve block. [ Time Frame: At 30 minutes ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adults (>18yrs)
  • ASA 1-2

Exclusion Criteria:

  • BMI >30
  • Allergy to local anesthetics
  • Pre-existing gait disturbance
  • Pre-existing neuropathy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01655277


Locations
United States, New York
St. Luke's Roosevelt Hospital
New York, New York, United States, 10025
Sponsors and Collaborators
St. Luke's-Roosevelt Hospital Center
More Information

Responsible Party: Jeff Gadsden, Director of Regional Anesthesia, St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier: NCT01655277     History of Changes
Other Study ID Numbers: 11-202
First Posted: August 1, 2012    Key Record Dates
Last Update Posted: August 1, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Muscle Weakness
Paresis
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Pathologic Processes
Signs and Symptoms